Testosterone for Women (2026): Libido, Risks & How to Get It

Some should - but far fewer than social media suggests. For postmenopausal women with low sexual desire that causes them distress, carefully dosed transdermal testosterone has good evidence of modest benefit. For fatigue, mood, brain fog, weight, muscle or general "hormone balance," the evidence doesn't support it, and the long-term safety questions are real.

Testosterone has become one of the most talked-about treatments in women's health. Podcasts call it the missing piece of menopause care. Clinics advertise it for energy, confidence and "getting your spark back." Prescriptions have more than doubled in three years. And in September 2026, the FDA held its first public workshop dedicated to testosterone use in menopausal women.

At the same time, there's still no FDA-approved testosterone product for women in the US, the major medical societies endorse it for only one indication, and a new study presented in October 2026 raised a cardiovascular warning flag.

This guide separates what's proven from what's promised. It covers:

• Why testosterone is suddenly everywhere - the 2025-2026 developments
• What testosterone does in a woman's body, and how levels change with age
• What the research shows it helps - and what it doesn't
• Safety, including the 2026 heart study and what it can and can't tell us
• Side effects, who shouldn't take it, and why pellets and injections are discouraged
• How it's prescribed and monitored, and the alternatives (including newly expanded Addyi)
• Cost, insurance, pharmacy problems and getting it online

Testosterone for women at a glance

Five things converged: soaring off-label prescriptions, the FDA's first public workshop on testosterone for menopausal women, a new study linking testosterone to cardiovascular events, an updated ACOG menopause guideline, and the expansion of Addyi to postmenopausal women.

The FDA workshop

On September 17, 2026, the FDA's Office of Women's Health and its Center for Drug Evaluation and Research held a hybrid public workshop to examine the scientific evidence and knowledge gaps on testosterone in menopause (FDA event page; Federal Register notice). FDA staff stated plainly that there are no FDA-approved uses for testosterone therapy in menopausal women, acknowledged rising off-label use, and invited drug developers to engage with the agency. Speakers also revisited past failures: a testosterone gel program in the early 2010s missed its efficacy goals amid a high placebo response. The public comment period closed on October 19, 2026.

It was a scientific workshop, not an approval meeting. No product is under FDA review for this use that we're aware of, and any approval would be years away.

The prescription surge

An exclusive analysis for Reuters by the health data firm Truveta found the rate of women receiving a testosterone prescription rose 146% from January 2023 to July 2026 (Reuters, via CNN, Sept 2026). Clinicians interviewed described pharmacies delaying or declining some prescriptions and said most insurers don't cover testosterone for women.

Several forces are pushing in the same direction: renewed openness to hormones after the 2025 FDA label change, social media and podcasts promoting testosterone for energy and "vitality," cash-pay clinics with a business model built on hormones, and a real, long-ignored problem - midlife sexual distress - that until December 2025 had no FDA-approved treatment for postmenopausal women.

It's worth separating two things that often get blurred.

The legitimate part

Low desire that distresses women is common, under-discussed and under-treated. For years, many women raising it were told it was "just aging" or offered nothing. The evidence that transdermal testosterone helps some postmenopausal women with HSDD is real and has been summarized in major meta-analyses and international guidance since 2019. Wanting a treatment for that - and being frustrated that the US has no approved female product - is entirely reasonable.

The overreach

The surge has also carried testosterone far beyond its evidence: marketed as a fix for fatigue, brain fog, motivation, body composition and "optimization," often via pellets or injections at doses that push levels into the male-to-female gray zone. Some clinics measure a blood level, call it low and prescribe on that basis, even though no level defines deficiency in women.

Why the gap matters

• Expectations: women who start testosterone for energy are likely to be disappointed - and may escalate the dose looking for an effect.
• Safety: the one area where we do have a new signal - cardiovascular events - is exactly where high, unmonitored dosing would be most concerning.
• Access: as pharmacies tighten scrutiny on off-label prescriptions, women with a genuine indication can get caught in the same delays.

The honest middle ground: testosterone is neither a miracle nor a menace. Used for the right reason, at the right dose, with monitoring, it's a reasonable option. Used for the wrong reasons or at the wrong dose, it's a gamble with unknown long-term odds.

Testosterone is a normal female hormone. Women make it in the ovaries and adrenal glands, and in larger amounts than estrogen in absolute terms. It contributes to sexual desire and arousal and acts on muscle, bone, brain and skin - partly directly and partly after conversion to estradiol.

We think of testosterone as the "male hormone," but women's ovaries and adrenal glands produce it throughout life, and some is made in tissues from precursor hormones such as DHEA. Women's levels are roughly one-tenth to one-twentieth of men's.

Where it acts

• Brain: involved in sexual motivation and desire.
• Genital tissue: supports blood flow and sensitivity.
• Muscle and bone: contributes to strength and bone density, though in women much of the bone effect runs through estradiol.
• Skin and hair: drives oil production and body hair growth - which is why excess causes acne and unwanted hair.

Free vs bound testosterone

Most testosterone in blood is bound to sex hormone-binding globulin (SHBG) and isn't active. Oral estrogen raises SHBG, which lowers the free, active fraction - one reason some clinicians prefer transdermal estrogen when a woman's main concern is desire. See estrogen patch vs pill.

Not suddenly. Women's testosterone declines gradually with age, starting in the 20s, and the ovaries keep producing some after natural menopause. The exception is surgical menopause: removing both ovaries causes an abrupt drop.

This surprises many women. Estradiol falls sharply around menopause; testosterone doesn't. Studies of healthy women show levels in the 40s are substantially lower than in the early 20s - a slow decline over decades - with no dramatic change at the final period.

The practical takeaway: low desire in midlife usually isn't simply "low testosterone." It is shaped by sleep, night sweats, vaginal pain, mood, medications, stress, relationship factors and body image - which is why guidelines insist those are addressed before testosterone. For the broader picture, see perimenopause symptoms and our complete menopause guide.

No. There is no testosterone level that defines "deficiency" in women, and standard lab tests are imprecise at female levels. Blood tests are used to check a baseline and make sure treatment doesn't push levels above the normal female range - not to decide who needs testosterone.

This is one of the most important points in the whole topic, and one of the most commonly ignored by clinics selling testosterone. Studies have not found a level below which women reliably have low desire, and many women with low measured testosterone have normal sexual function. The Global Consensus Position Statement on testosterone for women (2019) - endorsed by menopause and endocrine societies worldwide - advises against using a blood level to diagnose HSDD.

Be wary of any service that measures testosterone (or saliva hormones), declares it "low," and prescribes on that basis alone. Diagnosis is clinical: it rests on your symptoms and how much they distress you.

HSDD is persistent low or absent sexual desire that causes personal distress and isn't better explained by another medical condition, medication, relationship problem or life stress. The distress part is essential: low desire that doesn't bother you isn't a disorder.

HSDD is the diagnosis that testosterone studies were built around, so understanding it matters. Clinicians typically look for:

• Reduced or absent sexual thoughts, fantasies or interest in sex
• Lasting for months, not a bad week
• Causing you distress - not your partner alone
• Not mainly due to pain with sex, depression, medications, relationship conflict, exhaustion or another condition

Distressing low desire is common. In the large US PRESIDE survey of more than 30,000 women published in 2008, roughly 1 in 10 reported low desire that caused them distress, and rates were highest in midlife.

What can masquerade as HSDD

Testosterone doesn't fix pain, exhaustion or a strained relationship - which is why it works best after those are addressed.

Changes in desire with age are common and not automatically a disorder. Many women shift from "spontaneous" desire - wanting sex out of the blue - to "responsive" desire that appears once intimacy begins. That shift is normal. It becomes a treatable problem when it causes you distress.

Sex researchers describe two broad patterns. Spontaneous desire arises on its own; responsive desire builds in response to touch, closeness or arousal. In long relationships and in midlife, responsive desire often becomes more prominent. Many women who believe their desire has "disappeared" find that it's still there once they're in a relaxed, comfortable context.

That matters because it changes what helps:

• If desire responds once things start, but you rarely start, the issue may be time, fatigue, comfort or relationship dynamics - things sex therapy and practical changes address well.
• If nothing sparks interest even in good circumstances, and that distresses you, HSDD is more likely, and medical treatment becomes more relevant.
• If sex hurts, desire often switches off protectively - treat the pain first.

Normalizing responsive desire isn't dismissing the problem. It's often the first step to getting the right treatment.

In trials of postmenopausal women with HSDD, testosterone improved arousal, orgasm and pleasure scores as well as desire. But if arousal or orgasm problems are caused by pain, nerve damage, medications (especially SSRIs) or pelvic floor dysfunction, testosterone alone is unlikely to fix them.

The Islam meta-analysis found improvements in arousal, orgasm, responsiveness and pleasure alongside desire. These are linked: more interest often means more arousal, and better arousal makes orgasm easier. But arousal and orgasm have other common causes in midlife - genital tissue changes from low estrogen, antidepressants, diabetes, pelvic floor tension or weakness - each with its own treatment. A pelvic floor physical therapist is an underused resource for orgasm difficulties and pain.

Before testosterone, check the common, fixable causes of low desire: pain with sex, poor sleep, depression or anxiety, medications, thyroid and iron problems, diabetes, alcohol, relationship strain and a partner's own sexual health. Fixing one of these is often more effective than any hormone.

This isn't a hoop to jump through before you "deserve" testosterone - it's how you find the treatment most likely to work.

Yes, modestly, for postmenopausal women with HSDD. A 2019 meta-analysis of 36 randomized trials including 8,480 women found testosterone improved desire, arousal, orgasm, pleasure, satisfying sexual events and sexual self-image, and reduced sexual distress, compared with placebo or comparator.

That meta-analysis, by Islam and colleagues in The Lancet Diabetes & Endocrinology, is the strongest summary of the evidence and the foundation of the 2019 global consensus. Its key findings:

• Postmenopausal women: statistically significant improvements across nearly every measure of sexual function.
• Premenopausal women: too few studies (three trials, 226 women) to draw conclusions.
• Route matters: oral testosterone worsened cholesterol (higher LDL, lower HDL); non-oral forms didn't.
• Side effects: more acne and hair growth than placebo, no serious adverse events in trials - but trials were short.

How big is the effect?

Modest on average. In the pivotal patch trials that underpin much of this evidence, women on testosterone typically reported roughly one additional satisfying sexual event a month compared with placebo - and placebo responses were large. Averages hide variation: some women describe a clear return of interest, while many notice little.

That's why guidelines recommend a time-limited trial: if it helps, continue with monitoring; if not, stop.

What "works" means to women

Trials measure events and scores, but women more often describe changes like these when testosterone helps: thinking about sex again, responding more easily to a partner's touch, orgasm being easier to reach, and feeling less distressed about the change in themselves. If none of these shift within three to six months, the treatment probably isn't working for you.

Not according to current evidence. Major guidelines - including the 2019 global consensus and ACOG's October 2026 menopause guideline - say there isn't enough evidence to recommend testosterone for fatigue, mood, cognition, hot flashes, sleep, bone, muscle or weight in women.

This is where marketing and medicine diverge most. Many women seeking testosterone want it for energy, motivation, brain fog or body composition, and some report feeling better. But controlled trials haven't shown reliable benefits for these outcomes, and positive anecdotes are hard to separate from placebo effects, simultaneous changes (such as starting estrogen or exercising more), and expectation.

The October 2026 ACOG guideline - its first full update on menopause symptoms since 2014 - specifically concluded that evidence doesn't support testosterone for vasomotor, sleep or mood symptoms. For those, estrogen-based therapy and evidence-based non-hormonal treatments come first. See what is HRT?

Several reasons, and they're not mutually exclusive: some women genuinely respond strongly; placebo responses in sexual-function trials are large; testosterone is often started alongside other changes such as estrogen, better sleep or a new relationship; and people tend to seek treatment when symptoms are at their worst, so some improvement would happen anyway.

Trial averages describe groups, not individuals. Within the "modest average benefit," there are women who respond well and women who don't respond at all. That's why the time-limited trial matters: it lets you find out which group you're in.

The flip side is that stories of transformation on social media can't tell you how much was testosterone. Women in placebo groups in testosterone trials also reported meaningful improvements - a reminder that attention, expectation and simply addressing the problem are powerful. None of this makes anyone's improvement "fake"; it means anecdotes can't substitute for trials when weighing risks.

Estrogen is the main treatment for hot flashes, night sweats, vaginal dryness and bone protection. Testosterone's established role is narrower: distressing low desire. They complement each other but aren't interchangeable.

For the estrogen side, see what is HRT?, bioidentical hormones and our progesterone guide.

ACOG's Clinical Practice Guideline No. 13, published online October 15, 2026, replaces its 2014 menopause practice bulletin and covers hot flashes, sleep and mood. On testosterone, it concludes the evidence doesn't support using it for those symptoms. Sexual desire is addressed in ACOG's separate guidance on female sexual dysfunction.

The update is significant: it's ACOG's first comprehensive rewrite of menopause symptom management in over a decade, arriving after the FDA's hormone-therapy label changes (ACOG announcement). For testosterone, the message is consistent with the global consensus - it isn't a hot flash, sleep or mood treatment.

ACOG's separate sexual-dysfunction guidance has supported considering short-term transdermal testosterone for postmenopausal women with sexual interest and arousal disorders, after counseling about risks and unknown long-term effects, with a 3-6 month trial and testosterone levels checked at baseline and after 3-6 weeks.

At doses that keep blood levels in the normal female range, transdermal testosterone appears safe in the short term - trials lasting up to about two years didn't show serious harms. Long-term safety, especially for the heart and breast, hasn't been established, and a 2026 observational study raised a cardiovascular concern.

What we know

• Cholesterol: oral testosterone harms lipids; transdermal testosterone at female doses hasn't shown the same effect.
• Breast: short-term trial data haven't shown an increase in breast cancer, but trials were too short to rule out long-term effects. The consensus statement urges caution in women with hormone-sensitive breast cancer. For estrogen and progesterone, see HRT and breast cancer risk.
• Uterine lining: no clear signal in trials, though most participants were also on estrogen.
• Liver: non-oral routes avoid the liver effects seen with oral testosterone.

What we don't know

• Whether years of use change heart attack, stroke or blood clot risk
• Whether long-term use affects breast cancer risk
• The effects of the high doses many women receive from pellets and injections

At the September 2026 FDA workshop, speakers repeatedly flagged that the long-term safety evidence simply isn't there yet - which is exactly why the next study matters.

Possibly, but it isn't proven. A study presented at The Menopause Society's October 2026 annual meeting found that postmenopausal women who started testosterone had a cardiovascular event rate of about 3.8%, compared with 0.5% in similar women who didn't - roughly eight times higher. It was an observational analysis of health records that hasn't yet been peer-reviewed, so it shows an association, not cause and effect.

What the study did

Researchers used health records to compare more than 6,300 women aged 45 and older who started testosterone with matched women who didn't, excluding women with prior cardiovascular disease or recent testosterone use (Medical Xpress report). The combined rate of cardiovascular events - including heart attack and stroke - was 3.8% in testosterone users versus 0.5% in non-users.

How to read it

• Relative vs absolute: "eightfold" sounds alarming; the absolute difference was about 3 percentage points over the study period - meaningful, but most women in both groups had no event.
• Confounding: women prescribed testosterone may differ in ways records don't capture - for example, receiving higher-dose pellets or injections, or having other risk factors.
• Dose and form unknown: records may not show whether women used female-range transdermal doses or supraphysiologic forms.
• Not yet peer-reviewed: independent experts quoted by the UK Science Media Centre called the evidence suggestive and said more research is needed.

The Menopause Society's medical director, Dr. Stephanie Faubion, noted that cardiovascular disease is the leading cause of death in women and that long-term safety data on testosterone are lacking.

What it means for you

• If you have heart disease, prior stroke or several cardiovascular risk factors, the case for testosterone is weaker; discuss it carefully.
• If you use testosterone, stick to transdermal female-range doses with monitored levels.
• Keep blood pressure, cholesterol, blood sugar and smoking in check - they matter far more to your heart than any hormone.

The most common side effects are acne, oily skin and increased body or facial hair. At excessive doses, testosterone can cause scalp hair thinning, a deeper voice and clitoral enlargement - and voice changes may not reverse when you stop.

The pattern is consistent: most serious androgenic effects are dose-related. They're far more common when testosterone levels go above the female range - which is the main reason experts warn against pellets and injections.

Transfer to others

Testosterone gels and creams can transfer through skin contact. Apply to clean, dry skin (often the lower abdomen or thigh), wash your hands, and avoid skin-to-skin contact with children and partners until it dries. Male testosterone gels carry warnings about secondary exposure in children.

The US is not alone in lacking options, but it's behind some countries. Australia has a testosterone cream approved specifically for women, and UK guidance (NICE) suggests considering testosterone for menopausal women with low sexual desire when HRT alone hasn't helped. In most countries, as in the US, women's use is off-label.

The international picture reinforces the same message: where testosterone is used responsibly, it's for one indication, at female doses, with monitoring.

Testosterone isn't appropriate during pregnancy or breastfeeding, or for women who could become pregnant without reliable contraception. Extra caution - or avoidance - is needed with hormone-sensitive breast cancer, cardiovascular disease, liver disease, existing acne or excess hair growth, and conditions with high androgens such as PCOS.

• Pregnancy, breastfeeding or possible pregnancy: testosterone can masculinize a developing fetus. Perimenopausal women need reliable contraception.
• Hormone-sensitive breast cancer: the consensus statement advises caution; any use needs your oncologist.
• Heart disease, prior stroke or high cardiovascular risk: in light of the open safety questions and the 2026 study, the balance is less favorable.
• PCOS or other high-androgen conditions: levels may already be high.
• Severe acne, hirsutism or androgenic hair loss: likely to worsen.
• Active liver disease.
• Women whose low desire has another clear cause - pain, depression, medication or relationship issues - that hasn't been addressed.
• Athletes in tested sports: testosterone is prohibited by anti-doping rules.

And testosterone isn't a substitute for estrogen: it doesn't treat hot flashes or protect the uterus, and it doesn't treat vaginal dryness the way vaginal estrogen does.

Because no product is FDA-approved for women, US clinicians prescribe off-label - most often a testosterone gel or cream made for men, used at roughly one-tenth of the male dose, or a compounded cream. Experts recommend transdermal products that keep blood levels within the normal premenopausal female range.

The 2019 global consensus statement recommends doses that approximate physiological premenopausal testosterone concentrations, and says its recommendations don't extend to pellets, injections, compounded products or anything producing supraphysiological levels.

Forms compared

A brief history of why there's no US product

Women's testosterone products have reached the FDA before. In 2004, an FDA advisory committee declined to support a testosterone patch for women, citing insufficient long-term safety data; the patch was later approved in Europe for women after surgical menopause and then withdrawn for commercial reasons. A US testosterone gel for women failed its efficacy trials in the early 2010s amid a high placebo response - a history revisited at the 2026 FDA workshop.

Typical practice: measure total testosterone before starting, start a low transdermal dose, recheck levels after about 3-6 weeks to make sure they're within the female range, and assess benefit over 3-6 months. If there's no meaningful improvement by six months, stop. If it helps, continue with monitoring at least yearly.

This schedule reflects guidance summarized from ACOG's female sexual dysfunction recommendations and the global consensus approach. Your clinician may adapt it.

Practical tips

• Apply at the same time daily to clean, dry skin on the lower abdomen or upper thigh, rotating spots.
• Use the measuring method your prescriber specifies - with male gels, precise small amounts matter.
• Don't apply to the breasts or genitals unless specifically instructed.
• Wait to see benefit: changes often take several weeks to a few months.
• Report acne, hair growth, voice change or irritability promptly.

Pellets release testosterone continuously for months, often producing blood levels well above the normal female range. Once placed, they can't easily be removed or adjusted if side effects appear, and they aren't FDA-approved for women. The global consensus explicitly excludes them from its recommendations.

Pellet clinics often market "bioidentical hormone optimization" packages that combine testosterone and estradiol pellets, sometimes with blood tests used to justify higher dosing. The concerns:

• Supraphysiologic levels - more acne, hair growth, voice change and possibly cardiovascular risk.
• No off switch - if side effects develop, you wait months for the pellet to wear off.
• Estradiol pellets can also deliver very high estrogen levels; women with a uterus still need a progestogen.
• Cost - pellet insertion is usually cash-pay and often expensive per procedure.

If you're currently using pellets and have side effects, talk to a menopause-informed clinician about switching to an adjustable transdermal option once the pellet wears off.

Compounded testosterone creams aren't FDA-approved, and their strength can vary from batch to batch. The global consensus recommends against compounded testosterone, though some clinicians still use it because no approved female product exists in the US.

The appeal is real: a pharmacy can make a cream in a female-sized dose that's easier to measure than a fraction of a male gel. But without FDA oversight of the finished product, you can't be sure each batch delivers the labeled amount - which matters for a hormone where too much causes irreversible effects.

If your clinician prescribes compounded testosterone, ask why, which pharmacy makes it (a licensed 503A pharmacy, or a 503B outsourcing facility), and how they'll monitor your levels. The same FDA-approved-versus-compounded question applies to estrogen; see bioidentical hormones explained.

Usually, the menopause basics come first. Clinicians generally recommend treating vaginal dryness and painful sex, hot flashes, sleep and mood before trying testosterone, because those are common, treatable causes of low desire. The UK's NICE guideline suggests considering testosterone for menopausal women with low sexual desire if HRT alone hasn't helped.

• Painful sex? Start with vaginal estrogen, lubricants and possibly pelvic floor physical therapy.
• Hot flashes and night sweats wrecking sleep? Systemic HRT is the most effective treatment; better sleep often restores some desire.
• On oral estrogen? It raises SHBG and lowers free testosterone; switching to transdermal estrogen is a reasonable step before adding testosterone.
• On an SSRI? Discuss whether an alternative might affect desire less.

Most trials of testosterone in postmenopausal women included women also taking estrogen, though some studied testosterone without it. Testosterone doesn't protect the uterine lining or relieve hot flashes, so it isn't a replacement for HRT. For the HRT side, see is HRT safe? and estrogen patch vs pill.

Women who have both ovaries removed lose a large share of their testosterone production suddenly, and some of the earliest testosterone trials were in surgically menopausal women. The same rules apply: it's for distressing low desire, at female doses, with monitoring.

A hysterectomy that leaves the ovaries in place doesn't cause the same drop. If you've had both ovaries removed - especially before natural menopause - estrogen replacement is usually recommended until around the average age of menopause, and testosterone can be considered if desire doesn't recover. See how to get HRT online, which covers HRT after hysterectomy and early menopause.

The evidence for testosterone is in postmenopausal women; there's too little data in premenopausal and perimenopausal women to show benefit. If you're still having periods, pregnancy is also possible, and testosterone must not be used in pregnancy.

Low desire in perimenopause is common, but so are its other drivers: erratic hormones, heavy periods and iron deficiency, night sweats, stress and sleep loss. Those are usually addressed first - often with HRT, contraception that suits you, or treatment for heavy bleeding. See HRT for perimenopause. Some clinicians do prescribe testosterone in late perimenopause after counseling about the limited evidence; if you go that route, use reliable contraception.

Alternatives include treating the causes (vaginal estrogen for pain, HRT for sleep-wrecking night sweats, changing medications), sex therapy and mindfulness-based approaches, and two FDA-approved desire medicines: Addyi (flibanserin), which since December 2025 is approved for postmenopausal women under 65, and Vyleesi (bremelanotide), approved for premenopausal women.

The Addyi expansion matters because it gives postmenopausal women under 65 an FDA-approved option for the first time. It isn't a hormone and works differently, so some women who don't want testosterone may prefer it - and some who don't respond to one may respond to the other. Neither is a quick fix: both produce modest average benefits.

What about "female Viagra" creams?

Sildenafil (Viagra) improves blood flow, which is about arousal, not desire, and evidence in women is inconsistent. Some telehealth services sell compounded sildenafil arousal creams - Winona's is called Blossom (see Winona products explained). These aren't FDA-approved and aren't a treatment for low desire.

Ranked by the quality of evidence for distressing low desire after menopause: transdermal testosterone and Addyi have randomized-trial evidence of modest benefit; psychological approaches such as sex therapy and mindfulness have good supporting evidence; treating pain and sleep has strong indirect evidence; most supplements and pellets have little or none.

The best results usually come from combining approaches: treating the physical basics, addressing the psychological and relationship side, and - where distressing low desire remains - a monitored medication trial.

There's no head-to-head trial, so neither is proven better. Testosterone has broader evidence across sexual function but no FDA approval for women and uncertain long-term safety; Addyi is FDA-approved for postmenopausal women under 65 but requires a daily pill and caution with alcohol and certain medications.

Practical framing many clinicians use: women who prefer to avoid hormones, or who have reasons to be cautious about testosterone, may start with Addyi; women already on HRT who want a hormonal approach may try testosterone. Either way, try it for long enough to judge, and stop if it doesn't help.

Yes, from some telehealth services. Testosterone is a Schedule III controlled substance, but federal telemedicine flexibilities - extended through December 31, 2026 - let DEA-registered clinicians prescribe it after a video visit. Of the menopause providers we review, Midi Health lists testosterone in some states as a self-pay service, and LifeMD says its clinicians can assess testosterone for eligible women after a video visit.

The provider picture

See our Midi Health cost guide for visit pricing with and without insurance.

The DEA deadline

Since the pandemic, the DEA has allowed controlled substances to be prescribed by telemedicine without an in-person visit. Those flexibilities have been extended several times, most recently through December 31, 2026. Permanent rules are still being worked out; if they change, some online testosterone prescribing could require an in-person visit or special registration. If you start testosterone online, ask your provider how they'll handle that.

Red flags in online testosterone services

• Prescribing based on a blood level alone, without assessing desire and distress
• Promises of more energy, weight loss, confidence or "optimization"
• Pellets or injections as the default
• No follow-up blood tests
• Bundles of compounded hormones with saliva testing
• No discussion of risks or alternatives

Most US insurers don't cover testosterone for women because it isn't FDA-approved for them, so many women pay cash. Off-label use of a generic male gel can be relatively inexpensive at a female dose because one package lasts a long time; compounded creams, pellets and specialty clinic packages cost more.

HSA and FSA funds can generally be used for prescription medicines. Compare overall menopause care costs in our online HRT cost comparison.

Because testosterone is a controlled substance prescribed off-label at unusual doses, some pharmacies apply extra scrutiny - verifying prescriptions, questioning dosing, or declining to fill. Reuters reporting in September 2026 described delays and denials at several pharmacies, while CVS said its pharmacies regularly fill testosterone gel prescriptions for women.

Clinicians interviewed by Reuters described prescriptions being rejected or delayed, sometimes for a substantial share of their patients. What helps:

• Ask your prescriber to note the diagnosis (HSDD) and the intended female dose clearly on the prescription.
• Use a pharmacy that already fills your prescriber's testosterone prescriptions.
• Expect the pharmacist may call your prescriber - it's routine for controlled substances.
• If declined, ask why, and have your prescriber send it elsewhere rather than switching to an unregulated source.

Never buy testosterone from websites that don't require a prescription. Products from unregulated sources may be counterfeit, contaminated or wrongly dosed.

Ask what's driving your low desire, whether other causes have been addressed, which product and dose you'd use, how levels will be monitored, what side effects to watch for, how long the trial will last, and what happens if it doesn't help.

About the diagnosis

• Do my symptoms fit HSDD, or could pain, sleep, mood, medications or relationship factors explain them?
• Should we treat vaginal symptoms or hot flashes first?
• Is my estrogen route (pill vs patch) affecting my free testosterone?

About the treatment

• Which product will I use - an FDA-approved male product at a reduced dose, or compounded? Why?
• How exactly do I measure and apply my dose?
• When will you check my levels, and what range are we aiming for?
• How will we decide whether it's working, and when do we stop?

About safety

• Given my heart and breast history, is testosterone a reasonable option for me?
• What side effects should I report right away?
• Would Addyi or non-drug approaches be better first steps for me?

Not reliably at female doses. Studies in women haven't shown consistent gains in muscle, strength or bone density from testosterone, and the global consensus found insufficient evidence to recommend it for these uses. Resistance training, adequate protein and estrogen therapy (for bone) have far better evidence.

This is a common reason women ask about testosterone - especially those lifting weights or worried about osteoporosis. The reasoning seems intuitive: testosterone builds muscle in men. But women's doses are kept within the female range precisely to avoid masculinizing effects, and at those levels the muscle and bone effects in trials have been small or inconsistent.

• For muscle: progressive resistance training two or more times a week and protein spread across meals.
• For bone: estrogen prevents bone loss and reduces fractures; weight-bearing exercise, calcium and vitamin D help; bone medicines treat osteoporosis. Ask about a DXA scan if you're at risk.
• On a GLP-1? Muscle protection matters even more - see GLP-1s and menopause.

The core test is total testosterone - before starting and a few weeks after - to keep levels within the female range. Clinicians may also check SHBG, and consider lipids and other tests based on your health. Equally important are regular checks for acne, hair growth, voice change and mood.

One technical note: lab tests designed for men's higher levels can be inaccurate at women's low levels. Ask whether your lab uses a sensitive method such as mass spectrometry, especially if results don't match how you feel.

A good consultation spends more time on your symptoms, relationship and health history than on a blood test. It covers other causes, alternatives, risks including the open safety questions, a specific product and dose, a monitoring plan and a stop rule.

Signs of a careful clinician

• Asks about distress, pain, sleep, mood, medications and relationship factors
• Explains that testosterone is off-label and long-term safety is uncertain
• Mentions alternatives, including Addyi and sex therapy
• Recommends transdermal, female-range dosing
• Sets up blood tests and a 3-6 month review
• Is happy for you to stop if it doesn't help

Signs to walk away

• "Your levels are low, you need testosterone" based on a test alone
• Pellets or injections as the default
• Promises about energy, weight, youth or performance
• Packages bundling multiple compounded hormones
• No discussion of risks

It depends mostly on the route and the care model. A monitored transdermal regimen through a menopause clinic is usually far cheaper than pellet-based "hormone optimization" packages. These illustrative estimates show how the costs add up; your real costs will vary.

Insurance rarely covers testosterone for women. Labs may be covered. Use HSA or FSA funds where eligible, and confirm all prices directly - they change.

No - systemic testosterone isn't a treatment for vaginal dryness or the tissue changes of menopause. Low-dose vaginal estrogen is the first-line prescription; vaginal DHEA (prasterone) and ospemifene are alternatives. Vaginal testosterone has been studied in small trials, mainly in women on aromatase inhibitors, but isn't standard care.

This confusion is common because dryness, pain and low desire often travel together. If sex is uncomfortable, treating the tissue usually comes first - and often restores some desire on its own. See our vaginal estrogen guide for cream vs tablet vs ring.

Yes, potentially. Testosterone can enhance the effect of some blood thinners, may change insulin or diabetes medication needs, and can add to fluid retention with corticosteroids. Tell your prescriber about everything you take, including supplements such as DHEA.

• Warfarin and other anticoagulants: testosterone labels warn about changes in anticoagulant effect; monitoring may need to increase.
• Diabetes medicines: androgens can affect blood sugar control.
• Corticosteroids: possible additive fluid retention.
• Oral estrogen: raises SHBG, lowering free testosterone - which can change how much testosterone you seem to need.
• Other hormones and supplements: DHEA and "testosterone boosters" can add to androgen exposure.

Low desire is often experienced as a relationship problem even when its causes are physical, so talking openly helps whichever treatment you choose. Framing it as a shared, common, treatable issue - not a rejection - makes it easier for both partners.

• Name it without blame: "My desire has changed with menopause, and it's bothering me. I'm looking into why."
• Share what helps: more time, less pressure, more non-sexual touch, addressing pain.
• Reset expectations: responsive desire is normal; waiting for spontaneous desire may mean waiting a long time.
• Consider sex therapy together: it has good evidence and works alongside medication.
• Be clear about treatment: testosterone is a trial, not a guarantee; agree to review it together.

Remember that HSDD is defined by your distress, not a partner's. Treatment is for you, if and when you want it.

Short answers to the questions women ask most often about testosterone, based on the evidence and guidance above.

Can women use men's testosterone gel?

Yes, off-label, at roughly one-tenth of a typical male dose, measured carefully and monitored with blood tests. This is how many US menopause specialists prescribe it.

How long does testosterone take to work?

Allow three to six months. Some women notice changes in a few weeks; if there's no clear benefit by six months, it's unlikely to help.

Will testosterone make me aggressive?

Not at female-range doses for most women. Irritability has been reported with high levels - another reason to monitor.

Can testosterone change my voice?

Voice deepening is rare at female doses but can occur with excessive levels and may be permanent. Report hoarseness or voice changes promptly.

Is testosterone a controlled substance?

Yes. It's Schedule III in the US, which is why prescriptions face extra pharmacy checks and why telehealth prescribing depends on DEA rules.

Can I buy testosterone without a prescription?

Not legally in the US. Sellers offering it without a prescription are a safety risk; "testosterone boosters" sold as supplements aren't testosterone and aren't proven to help.

Does testosterone affect fertility or pregnancy?

It must not be used in pregnancy because it can harm a developing fetus. Women who could become pregnant need reliable contraception.

Can I use testosterone without estrogen?

Some trials studied testosterone without estrogen, and some women use it that way. But many women's desire also depends on treating estrogen-related symptoms, so the two are often combined.

Will it help my hot flashes?

No. Testosterone isn't a treatment for hot flashes; estrogen-based HRT and non-hormonal medicines are - see hot flash treatments ranked.

Trials found a small average weight gain in women using testosterone compared with placebo. It isn't a weight-loss treatment, and claims that it helps women "burn fat" aren't supported by trials in women.

Midlife weight gain has many drivers - aging, lower muscle mass, sleep loss, less activity and the shift of fat toward the waist after menopause. If weight is your main concern, evidence-based options include nutrition and strength training and, where appropriate, GLP-1 medicines - covered in our GLP-1s and menopause guide.

Look for a clinician with menopause training - for example, a Menopause Society Certified Practitioner (MSCP) - or a gynecologist, endocrinologist or sexual medicine specialist experienced in female sexual dysfunction. Online menopause clinics with video visits are another route.

• The Menopause Society lists certified practitioners in a searchable directory.
• Sexual medicine specialists (some affiliated with the International Society for the Study of Women's Sexual Health) focus on desire, arousal and pain.
• Online menopause clinics: Midi Health prescribes testosterone in some states after a video visit. Compare options in our online HRT providers comparison.
• Your own doctor: bring this guide's checklist and questions; many primary care clinicians will prescribe with appropriate monitoring.

Changes are gradual. Some women notice more interest within a few weeks, but guidelines allow three to six months to judge. Blood levels are checked early to make sure the dose isn't too high, and the trial ends if there's no meaningful benefit by about six months.

Keeping a short weekly note - desire, arousal, satisfaction and any side effects - makes the six-month decision much easier and more honest than relying on memory.

Benefits usually fade over weeks to months after stopping, as levels return to baseline. Side effects such as acne and oily skin generally resolve; unwanted hair growth slows but existing hairs may need removal; voice deepening and clitoral enlargement, if they occurred, may not fully reverse.

There's no withdrawal syndrome at female doses, and you don't need to taper in most cases - but discuss it with your prescriber, especially if you're on other hormones. If you stop because it didn't help, that's useful information: it points toward other causes or treatments rather than a need for a higher dose.

Only with their oncology team's involvement, and generally with caution. Testosterone can be converted into estradiol in the body, long-term breast safety data are lacking, and the global consensus advises caution in women with hormone-sensitive breast cancer.

Breast cancer survivors often face severe sexual side effects - especially on aromatase inhibitors, which drive estrogen very low. The usual sequence is non-hormonal approaches first (moisturizers, lubricants, pelvic floor therapy, sex therapy), then, for vaginal symptoms, a careful discussion of options such as vaginal DHEA or low-dose vaginal estrogen with the oncologist. Some specialists use testosterone in selected survivors in research or specialist settings; it isn't a routine choice. Our vaginal estrogen guide covers the evidence on local estrogen after breast cancer.

It can, mainly when doses push levels above the normal female range. Women with a tendency to female-pattern hair thinning may be more sensitive. At carefully monitored female doses, scalp hair loss is uncommon.

Midlife hair thinning has many causes - falling estrogen, genetics, thyroid problems, iron deficiency, rapid weight loss and stress. If you notice thinning after starting testosterone, report it: a dose reduction or stopping often helps if caught early. Non-hormonal treatments such as minoxidil are commonly used for female-pattern hair loss regardless of testosterone.

Oral DHEA supplements aren't recommended for low desire in postmenopausal women - trials haven't shown consistent benefit, and supplement quality varies. Vaginal DHEA (prasterone) is different: it's an FDA-approved prescription for painful sex due to menopause.

DHEA is a precursor hormone the body can convert into testosterone and estrogens, and it's sold over the counter as a supplement in the US. Because supplements aren't held to drug standards, the dose on the label may not match what's in the bottle, and side effects such as acne and hair growth can occur. If you're drawn to DHEA because you want a "gentler" option, a monitored, prescribed treatment is safer than a supplement of uncertain strength.

There's less evidence for women over 65, and cardiovascular risk rises with age, so the balance of benefit and risk is less certain. Some older women with distressing low desire do use it after careful discussion; Addyi's expanded approval is for postmenopausal women under 65.

If you're over 65, a thorough look at heart risk factors, medications (many of which affect desire) and any vaginal symptoms is especially important. Treating painful sex with vaginal estrogen is often the most effective step at this age. If testosterone is tried, the same rules apply: transdermal, female range, monitored, time-limited.

Think of testosterone as a possible later step, not the first one. A sensible order: identify what's bothering you most, treat vaginal and urinary symptoms, treat hot flashes and sleep, address mood and medications, add psychological or couples support, then consider a monitored trial of testosterone or Addyi for distressing low desire that remains.

1. Name the problem: low desire, pain, arousal, orgasm or relationship distress? They have different treatments.
2. Fix pain first: vaginal estrogen, lubricants, moisturizers, pelvic floor therapy.
3. Treat the menopause basics: HRT if appropriate for hot flashes and sleep - ideally transdermal estradiol. See how to get HRT online.
4. Review medications that dampen desire.
5. Consider sex therapy or mindfulness-based approaches - helpful on their own or with medication.
6. If distressing low desire persists: discuss a 3-6 month trial of transdermal testosterone, or Addyi if you're under 65 and prefer a non-hormonal pill.
7. Review honestly: continue only if it clearly helps.

Not soon. The September 2026 workshop signaled that the FDA is open to approving a women's testosterone product and wants companies to bring one forward, but any approval would need new trials showing benefit and, crucially, long-term safety. That process typically takes years.

What could happen next:

• New trials: at least one US trial of a transdermal testosterone gel for female sexual interest and arousal disorder in peri- and postmenopausal women is registered on ClinicalTrials.gov.
• Safety studies: the FDA has emphasized that long-term cardiovascular data are inadequate; the October 2026 observational study will add pressure for well-designed safety trials.
• Public comments: the docket that closed October 19, 2026 included calls from consumer groups such as Public Citizen to require robust safety evidence before any approval.

Until then, testosterone for women in the US remains off-label - legal and common, but without an FDA-reviewed product, label or dosing designed for women.

You're more likely to be a reasonable candidate if you're postmenopausal, your main problem is low desire that distresses you, other causes have been addressed, and you don't have heart disease, hormone-sensitive cancer or high-androgen conditions. Use this checklist to prepare for a conversation with your clinician - not to decide on your own.

Apply the measured dose to clean, dry skin on the lower abdomen or upper thigh at the same time each day, let it dry, wash your hands, and keep the area covered or away from others' skin until it's absorbed. Follow your prescriber's exact measuring method.

1. Measure precisely: with male gels, women use a small fraction of a pump or packet; your prescriber may suggest a syringe or a specific method. Don't eyeball it.
2. Choose the site: lower abdomen, outer thigh or buttock are common; rotate within the area.
3. Rub in until absorbed and let it dry before dressing.
4. Wash your hands thoroughly with soap and water.
5. Avoid transfer: no skin-to-skin contact with children or partners on the application site until dry; washing the area before contact also helps.
6. Avoid showering or swimming for a few hours after application, as product labels advise.
7. Keep it locked away from children; it's a controlled substance.

Androgens have been used in women's health for decades, but no product has completed the modern FDA path for women's sexual desire - a history of near-misses that explains why US women still rely on off-label prescribing in 2026.

The biggest gaps are long-term cardiovascular safety, long-term breast safety, effects in perimenopausal women, the right dose and formulation for women, and whether any benefits beyond desire are real. An FDA-approved women's product would require trials addressing several of these.

• Heart: randomized trials long enough to detect heart attacks and strokes, ideally at female-range transdermal doses - the 2026 observational signal makes this urgent.
• Breast: multi-year safety data, especially in women with higher baseline risk.
• Perimenopause: trials in women still cycling, where demand is high and evidence thin.
• Formulation: a women's product with accurate small doses would remove the guesswork of using male gels.
• Beyond desire: rigorous trials on energy, mood, cognition and muscle to settle the claims either way.

We'll update this guide as results arrive - including peer-reviewed publication of the October 2026 cardiovascular study.

If you already use testosterone, the 2026 developments are a good prompt for a review: confirm the form and dose, check that your levels are in the female range, look honestly at whether it's still helping, and discuss your cardiovascular risk with your prescriber. Don't stop or change doses on your own without a plan.

If you're on pellets and want to switch, ask about moving to an adjustable transdermal dose once the pellet's effect has worn off, with levels checked before restarting.

Prescription testosterone is the hormone itself. DHEA is a precursor the body converts partly into testosterone and estrogens - available as an FDA-approved vaginal insert and as unregulated oral supplements. "Testosterone boosters" are supplement blends that don't contain testosterone and lack good evidence.

Experts broadly agree on the core: HSDD after menopause is the evidence-based indication, transdermal female-range dosing is safest, and pellets and supraphysiologic dosing should be avoided. They disagree on how far beyond that to go - especially for energy, mood and brain fog, in perimenopause, and on compounded products.

• Broader use: some menopause clinicians report that selected women describe improved energy or well-being and are willing to offer a monitored trial; guideline bodies say the evidence doesn't support it. Both sides agree better trials are needed.
• Perimenopause: some clinicians prescribe in late perimenopause; others wait for menopause because of thin evidence and pregnancy risk.
• Compounded creams: the global consensus recommends against them; some US clinicians use them because there's no approved women's product and measuring tiny amounts of male gel is impractical.
• The 2026 heart study: some experts see it as a meaningful warning; others emphasize its observational design and the likelihood that high-dose forms drove the signal.

Where experts disagree, your preferences and risk tolerance legitimately shape the decision. A good clinician will tell you which parts of their advice are guideline-backed and which are clinical judgment.

These are illustrative examples, not real patients or medical advice. They show how the factors in this guide shape different decisions.

Scenario 1: 54, on HRT, desire still gone

Two years after menopause, on an estradiol patch and progesterone, hot flashes are controlled and sleep is good. Sex isn't painful, but she rarely thinks about it, and that distresses her. After discussing options, she starts a monitored trial of a small transdermal testosterone dose, with levels checked at six weeks and a review at four months. It's a reasonable candidate case.

Scenario 2: 51, sex hurts

Desire has dropped, but sex has become painful with dryness and burning. Her clinician starts vaginal estrogen; after three months, comfort returns and so does much of her interest. Testosterone was never needed.

Scenario 3: 47, wants testosterone for energy

Exhausted, foggy, still having irregular periods, with heavy bleeding. Testing shows iron-deficiency anemia. Treating the anemia and heavy periods, plus HRT for night sweats, helps her energy. Testosterone isn't supported for fatigue and, with possible pregnancy, wasn't appropriate.

Scenario 4: 60, heart disease

Prior heart attack, distressing low desire. Given the open cardiovascular questions, she and her cardiologist decide against testosterone; she tries sex therapy and, with her cardiologist's input on drug interactions, discusses Addyi.

• Testosterone: an androgen hormone made by the ovaries and adrenal glands in women.
• Androgen: a class of hormones, including testosterone and DHEA, with "masculinizing" effects at high levels.
• HSDD (hypoactive sexual desire disorder): persistent low desire that causes distress and isn't explained by another cause.
• FSIAD: female sexual interest/arousal disorder, a related diagnostic category.
• SHBG (sex hormone-binding globulin): a protein that binds testosterone; oral estrogen raises it.
• Free testosterone: the unbound, active fraction.
• Transdermal: absorbed through the skin (gel, cream).
• Supraphysiologic: above the normal range for the body.
• Off-label: prescribing an approved drug for a use, population or dose not on its label.
• Compounded: mixed by a pharmacy for an individual; not FDA-approved.
• Schedule III: the US controlled-substance category that includes testosterone.
• Surgical menopause: menopause caused by removal of both ovaries.
• GSM: genitourinary syndrome of menopause - vaginal and urinary changes from low estrogen.
• Flibanserin (Addyi): a non-hormonal daily pill for HSDD.
• Bremelanotide (Vyleesi): an as-needed injection for HSDD in premenopausal women.

We built this guide from FDA materials, peer-reviewed research, professional guidelines and reporting on 2026 developments, checked on October 31, 2026. Where findings are preliminary - such as the October 2026 cardiovascular study, which hasn't yet been peer-reviewed - we say so.

We don't recommend specific doses, we don't promote pellets or compounded testosterone, and we only report provider details we could verify. HRT Women earns commissions from some providers; that doesn't change what the evidence says. Read our medical review policy and how we rank providers.

Testosterone is a legitimate, evidence-based option for one specific problem - distressing low sexual desire after menopause - when used at female doses, through the skin, with monitoring and a clear stop rule. It's not a cure-all, it's not FDA-approved for women, and its long-term safety is genuinely uncertain. The 2026 hype has run ahead of the science; the 2026 science is catching up.

Your next steps

1. Get specific: is the problem desire, pain, arousal, orgasm or exhaustion?
2. Treat the foundations: vaginal symptoms, hot flashes, sleep, mood and medications.
3. If distressing low desire remains: ask a menopause-informed clinician about a 3-6 month trial of transdermal testosterone - or Addyi if you're under 65 and prefer a non-hormonal option.
4. Insist on monitoring: baseline and follow-up levels, side-effect checks and a decision point.
5. Avoid: pellets, injections, oral testosterone, saliva-test "optimization" and prescription-free sellers.
6. Know your heart risk: blood pressure, cholesterol, blood sugar and smoking status matter.

Explore menopause care options in our comparison of online HRT providers and Midi Health review, and read the complete menopause guide for the bigger picture.

This article is general information, not medical advice. A licensed clinician should decide which treatment, if any, is right for you.

• FDA. Public workshop: Testosterone Use in Menopausal Women, September 17, 2026
• Federal Register. Testosterone Use in Menopausal Women; Public Workshop; Request for Comments (Aug 18, 2026)
• Reuters (via CNN). Testosterone scripts for women rise, along with denials and delays (Sept 2026)
• Testosterone therapy may increase risk of cardiovascular disease in postmenopausal women - Menopause Society 2026 annual meeting (Medical Xpress)
• Science Media Centre. Expert reaction to the Menopause Society press release on testosterone and cardiovascular disease
• Davis SR, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019
• Islam RM, et al. Safety and efficacy of testosterone for women: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019
• ACOG. Clinical Practice Guideline No. 13: management of menopause-related vasomotor, sleep and mood symptoms (Oct 2026)
• FDA approves expanded use of flibanserin for HSDD in postmenopausal women (Dec 2025)
• DEA extends telemedicine prescribing flexibilities through December 31, 2026
• The 2022 hormone therapy position statement of The North American Menopause Society